S-1/A: Incannex Healthcare Files S-1/A Amendment for Resale of 75.9 Million Shares

Incannex Healthcare is registering for resale up to 75.9 million shares of common stock by selling stockholders, including shares held, shares issuable upon exercise of pre-funded warrants, and shares issuable upon exercise of Series A warrants.

Summary

• Incannex Healthcare Inc. has filed an amendment to its Form S-1 registration statement to register the resale of up to 75,902,171 shares of its common stock by selling stockholders.
• The shares include 9,687,045 shares currently held, 1,887,045 shares issuable upon exercise of pre-funded warrants, and 64,328,081 shares issuable upon exercise of Series A warrants.
• The Series A warrants are not currently exercisable and will be exercisable following stockholder approval.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, except for nominal proceeds of $0.0001 per share upon the cash exercise of the pre-funded warrants.
• The company is unlikely to receive any cash proceeds from the exercise of the Series A warrants as the Series A warrants may be exercised following stockholder approval on a zero exercise price basis where the holder will be eligible to receive, for each share of Common Stock issuable upon exercise of the Series A Warrant, three shares of our Common Stock without the payment of any exercise price.
• As of April 11, 2025, the securities registered for resale would represent approximately 275.5% of the outstanding shares and 20.1% of the total shares outstanding assuming the exercise of all Pre-Funded Warrants and the issuance of the maximum number of shares of Common Stock that may be issuable upon exercise of the Series A Warrants.
• Following and assuming our receipt of the Stockholder Approval to increase our authorized shares of Common Stock, we will be required to register an additional 282,894,619 shares of our Common Stock for resale.
• The securities to be registered for resale by the selling stockholders in the above referenced future resale registration statement and in the registration statement of which this prospectus forms a part would be approximately 1,260.5% of the 27,546,753 shares of our Common Stock outstanding as of April 11, 2025 and 92.19% of our total shares of Common Stock outstanding assuming the exercise of all Pre-Funded Warrants and the issuance of the maximum number of shares of Common Stock that may be issuable upon exercise of the Series A Warrants.
• The company's common stock is traded on the Nasdaq Global Market under the symbol IXHL, and the closing sale price on April 11, 2025, was $0.629 per share.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain reduced public company reporting requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential for significant dilution, Nasdaq listing compliance issues, and the company's lack of revenue. The reliance on future stockholder approval and the complex warrant structure add further uncertainty.

Positives

• The registration allows selling stockholders to offer and sell their shares, potentially increasing liquidity for the stock.
• The company is pursuing clinical-stage biopharmaceutical development, targeting chronic conditions with unmet needs.

Negatives

• The company will not receive significant proceeds from the resale of shares by selling stockholders.
• The potential resale of a large number of shares could significantly decrease the market price of the common stock and increase its volatility.
• The company is unlikely to receive any cash proceeds from the exercise of the Series A warrants as the Series A warrants may be exercised following stockholder approval on a zero exercise price basis where the holder will be eligible to receive, for each share of Common Stock issuable upon exercise of the Series A Warrant, three shares of our Common Stock without the payment of any exercise price.
• The company is currently non-compliant with Nasdaq listing rules regarding minimum market value of listed securities and market value of publicly held shares, potentially leading to delisting.
• The company is contractually prohibited pursuant to the terms of the March 2025 Purchase Agreements from effecting a reverse stock split of our Common Stock prior to September 6, 2025, unless we are expressly required to effect a reverse split as a result of changes in applicable laws effected after the closing of the Private Placement related to Nasdaq Listing Requirements or we obtain a waiver from the selling stockholders who purchased at least 50.1% of the Shares and Pre-Funded Warrants sold in the Private Placement.

Risks

• The potential resale of a large number of shares could significantly decrease the market price of the common stock and increase its volatility.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting, adversely affecting the company's ability to raise capital and the value of its stock.
• The company's reliance on stockholder approval for the exercise of Series A warrants introduces uncertainty and could impact its ability to raise capital.
• The company is contractually prohibited pursuant to the terms of the March 2025 Purchase Agreements from effecting a reverse stock split of our Common Stock prior to September 6, 2025, unless we are expressly required to effect a reverse split as a result of changes in applicable laws effected after the closing of the Private Placement related to Nasdaq Listing Requirements or we obtain a waiver from the selling stockholders who purchased at least 50.1% of the Shares and Pre-Funded Warrants sold in the Private Placement.
• The company is not profitable and does not expect to be profitable in the near term.

Future Outlook

The company intends to seek stockholder approval for the issuance of Series A warrant shares and an increase in the authorized number of shares of common stock. Following and assuming approval of the Charter Amendment Proposal, we will seek to register the remaining 282,894,619 shares of our Common Stock issuable upon exercise of the Series A Warrants.

Industry Context

Incannex Healthcare operates in the clinical-stage biopharmaceutical industry, focusing on developing combination medicines for chronic conditions. The company's programs target disorders with limited or inadequate treatment options.

Comparison to Industry Standards

• It is difficult to compare Incannex Healthcare's current financial situation to industry standards due to its clinical-stage nature and lack of revenue.
• Comparable companies would be other clinical-stage biopharmaceutical firms, particularly those focused on cannabinoid-based therapeutics.
• However, direct comparisons are challenging without detailed financial metrics and clinical trial data from competitors.
• The company's reliance on private placements and potential dilution from warrant exercises is a common financing strategy for companies in this sector, but the extent of potential dilution is significant.

Stakeholder Impact

• Shareholders may experience significant dilution and potential decline in stock price due to the resale of a large number of shares.
• Employees may face uncertainty due to the company's financial situation and potential delisting.
• Potential investors should be aware of the risks associated with the company's financial situation and the potential for significant dilution.

Next Steps

• Seek stockholder approval for the issuance of Series A warrant shares and an increase in the authorized number of shares of common stock.
• File an additional registration statement to register for resale the remaining Series A Warrants Shares, in an amount equal to 282,894,619, assuming full adjustment of the exercise price to the Floor Price, not registered in this registration statement on Form S-1.
• Regain compliance with Nasdaq listing rules to avoid delisting.

Key Dates

Keywords

resale, common stock, warrants, stockholder approval, IXHL, Incannex Healthcare, registration statement, private placement, securities, Nasdaq